---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-028054"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:45:54.061869+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Indaptus Q2 2023 cash $19.7M, Phase 1 trial advances; CMO appointed

## Summary
- Cash and marketable securities $19.7M as of June 30, 2023; runway into Q2 2024.
- Phase 1 trial (Decoy20) completed first cohort, authorized to advance to second; evidence of immune activation.
- Appointed Roger Waltzman, M.D. as Chief Medical Officer, effective Aug 7, 2023.
- Q2 2023 net loss per share $0.39 vs $0.46 prior year; G&A down to $2.0M.
- Patent allowances in Brazil and India expanded IP protection to 32 countries.

## SEC filing metadata
- accession: 0001493152-23-028054
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315223028054/0001493152-23-028054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315223028054/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-028054
- JSON: https://secwatch.observer/filing/0001493152-23-028054.json
- Plain text: https://secwatch.observer/filing/0001493152-23-028054.txt

## Key facts
- Earnings Releases
  Indaptus Therapeutics, Inc. reported second quarter ended June 30, 2023 results: EPS Loss per share for the three months ended June 30, 2023 was approximately $0.39.
  - Period: second quarter ended June 30, 2023
  - EPS: Loss per share for the three months ended June 30, 2023 was approximately $0.39
  - Result: reported results
  source text: Loss per share for the three months ended June 30, 2023 was approximately $0.39
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315223028054/0001493152-23-028054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.